The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluation of circulating tumor cells in stage III colorectal cancer patients under three or six months of adjuvant therapy.
 
Ippokratis Messaritakis
No Relationships to Disclose
 
Asimina Koulouridi
No Relationships to Disclose
 
Maria Sfakianaki
No Relationships to Disclose
 
Konstantinos Vogiatzoglou
No Relationships to Disclose
 
Nikolaos Gouvas
No Relationships to Disclose
 
Ioannis Tsiaousis
No Relationships to Disclose
 
Elias Athanasakis
No Relationships to Disclose
 
Evangelos Xynos
No Relationships to Disclose
 
Ioannis Sougklakos
Consulting or Advisory Role - Bristol-Myers Squibb-Ono Pharmaceutical; IPSEN (Inst); MSD; Pierre Fabre; Roche (Inst); SERVIER (Inst)
Speakers' Bureau - Merck KGaA (Inst); MSD; Roche (Inst); Sanofi
Research Funding - Amgen (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Amgen; Merck Serono; Roche; Sanofi; SERVIER
 
Ioannis Boukovinas
Employment - Pierre Fabre (I)
Honoraria - AstraZeneca; Bristol-Myers Squibb; LEO Pharma; Merck; MSD; Novartis; Pfizer; Roche; SERVIER
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genesis Pharma; Ipsen; LEO Pharma; MSD; Novartis; Roche; Sanofi
Research Funding - Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Regeneron; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; MSD; Pfizer; Roche; Servier